Is Kangfang Bio a state-owned enterprise or a private enterprise?

According to Aiqi's investigation, Kangfang Bio (9926.HK stock code: HKEx) was established on 20 12, which is a biopharmaceutical company dedicated to the research, development, production and commercialization of innovative antibody drugs affordable to patients all over the world. The company was officially listed on the main board of The Stock Exchange of Hong Kong Limited on April 24th, 2020. At present, the company has more than 30 innovative drug product lines for treating tumor, autoimmune, inflammation, metabolic diseases and other major diseases, among which 17 varieties have entered clinical research, including two new bispecific antibody drugs (PD- 1/CTLA-4 and PD- 1/VEGF) pioneered internationally. In August of 20021year, the company's first differentiated PD- 1 monoclonal antibody drug Anico? (Ampley monoclonal antibody injection) was approved for marketing. In June 2022, Kangfang Bio, the world's first tumor double immune checkpoint inhibitor, Cotanni? (PD- 1/CTLA-4 double antibody, cardenizumab injection) was approved for the treatment of cervical cancer. Kangfang Bio expects to innovate and develop new drugs with the best therapeutic effect of similar drugs through efficient and breakthrough research and development, and become a leading biopharmaceutical enterprise in the world. Enterprise type: limited liability company (invested by Hong Kong, Macao and Taiwan, not wholly owned), from which it is learned that Kangfang Bio is a private enterprise.